Literature DB >> 22759932

Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study.

Stefan Klingberg1, Jutta Herrlich, Georg Wiedemann, Wolfgang Wölwer, Christoph Meisner, Corinna Engel, Ute E Jakobi-Malterre, Gerhard Buchkremer, Andreas Wittorf.   

Abstract

This study examined the frequency and extent of detrimental effects of cognitive behavioral therapy (CBT) for psychosis. In a randomized clinical trial, we investigated the efficacy of CBT for the reduction of negative symptoms as compared with cognitive remediation (CR) in schizophrenia patients (n = 198). Safety was addressed through assessment of severe adverse events (SAEs), which were defined as suicides, suicide attempts, suicidal crises, and severe symptom exacerbations over a period of 12 months after inclusion in the study. Monthly assessments with Positive and Negative Syndrome Scale and Scale for the Assessment of Negative Symptoms allowed for the analysis of symptom increases during the treatment. There were no suicides in the trial. SAEs were observed in 10 CBT and 5 CR patients. Increases in negative symptoms occurred in 64 CBT and 58 CR patients. These differences were not significant. The maximum increase in negative symptoms under treatment, as compared with the baseline, was equal to an effect size of -0.66 in CBT patients and -0.77 in CR patients. Thus, the SAE rate was comparable between both interventions and was relatively low, given the severity of the psychotic disorder. Therapists should be aware of a subgroup of patients who show symptom increases with large effect sizes and might require more intensive care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22759932     DOI: 10.1097/NMD.0b013e31825bfa1d

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  7 in total

1.  [Evidence-based psychotherapy of schizophrenic psychoses].

Authors:  S Klingberg; A Wittorf
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

2.  Reporting and understanding the safety and adverse effect profile of mobile apps for psychosocial interventions: An update.

Authors:  Farooq Naeem; Nadeem Gire; Shuo Xiang; Megan Yang; Yumeen Syed; Farhad Shokraneh; Clive Adams; Saeed Farooq
Journal:  World J Psychiatry       Date:  2016-06-22

Review 3.  Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.

Authors:  Nicholas T Bello; Bryn L Yeomans
Journal:  Expert Opin Drug Saf       Date:  2017-10-31       Impact factor: 4.250

4.  The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial.

Authors:  Louise B Glenthøj; Birgitte Fagerlund; Lasse Randers; Carsten R Hjorthøj; Christina Wenneberg; Kristine Krakauer; Astrid Vosgerau; Christian Gluud; Alice Medalia; David L Roberts; Merete Nordentoft
Journal:  Trials       Date:  2015-01-27       Impact factor: 2.279

5.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

6.  Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia.

Authors:  Christopher Jones; David Hacker; Alan Meaden; Irene Cormac; Claire B Irving; Jun Xia; Sai Zhao; Chunhu Shi; Jue Chen
Journal:  Cochrane Database Syst Rev       Date:  2018-11-15

7.  Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial.

Authors:  Melissa Pyle; John Norrie; Matthias Schwannauer; David Kingdon; Andrew Gumley; Douglas Turkington; Rory Byrne; Suzy Syrett; Graeme MacLennan; Robert Dudley; Hamish J McLeod; Helen Griffiths; Samantha Bowe; Thomas R E Barnes; Paul French; Paul Hutton; Linda Davies; Anthony P Morrison
Journal:  BMC Psychiatry       Date:  2016-08-05       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.